Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTTO adjuvant HER2-positive breast cancer study
2006-000562-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lapatinib and trastuzumab in breast cancer (4 arms), sponsored by Novartis. Primary endpoint: Disease-free survival. Started Mar 2007; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000562-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000562-36.